FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN)

CUSIP: 35655L206

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / SPONSORED ADS
Total 13F shares
506,632
Share change
+506,632
Total reported value
$1,306,074
Price per share
$2.58
Number of holders
10
Value change
+$1,306,074
Number of buys
10

Quarterly Holders Quick Answers

What is CUSIP 35655L206?
CUSIP 35655L206 identifies FRLN - FREELINE THERAPEUTICS HLDGS - SPONSORED ADS in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) as of Q2 2023

As of 30 Jun 2023, FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) was held by 10 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 506,632 shares. The largest 10 holders included TFG Asset Management GP Ltd, TANG CAPITAL MANAGEMENT LLC, MORGAN STANLEY, UBS Group AG, RENAISSANCE TECHNOLOGIES LLC, CHI Advisors LLC, NORTHERN TRUST CORP, HARBOR CAPITAL ADVISORS, INC., ACADIAN ASSET MANAGEMENT LLC, and Aspire Private Capital, LLC. This page lists 10 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.